A multicentre, randomised clinical trial to evaluate the efficacy of oral ciprofloxacin, oral tamsulosin, and the combination of oral ciprofloxacin and oral tamsulosin for the treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome

ISRCTN ISRCTN85291415
DOI https://doi.org/10.1186/ISRCTN85291415
Secondary identifying numbers N/A
Submission date
30/06/2004
Registration date
11/11/2004
Last edited
25/08/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Kathleen Propert
Scientific

University of Pennsylvania School of Medicine
Blockley Hall 6th Floor
423 Guardian Drive
Philadelphia, PA
19104-6021
United States of America

Study information

Study designMulticentre randomised double blind placebo controlled 2x2 factorial trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedChronic Prostatitis (CP)/Chronic Pelvic Pain Syndrome (CPPS)
InterventionA 2x2 factorial design assessing four interventions: ciprofloxacin alone, tamsulosin alone, the combination of ciprofloxacin and tamsulosin, and placebo. All treatments were provided for six weeks.

Please note that as of 25/08/09 the start and end dates of this trial have been updated. The initial dates, 01/04/2002 to 30/04/2004, were generated at the time of registration.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Ciprofloxacin, tamsulosin
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/07/2001
Completion date30/09/2002

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexMale
Target number of participants184 (196 final [added 25/08/09])
Key inclusion criteriaApproximately 184 participants, 46 per arm, were treated and followed for a total of 12 weeks. These participants were male, had symptoms of discomfort or pain in the pelvic region for at least a 3 month period within the last 6 months, and had a overall score of equal to or greater than 15 out of 43 points on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.
Key exclusion criteriaDoes not match inclusion criteria
Date of first enrolment01/07/2001
Date of final enrolment30/09/2002

Locations

Countries of recruitment

  • United States of America

Study participating centre

University of Pennsylvania School of Medicine
Philadelphia, PA
19104-6021
United States of America

Sponsor information

Funders

Funder type

Government

National Institutes of Health (NIH) (USA) - cooperative agreements U01 DK53572, U01 DK53730, U01 DK53736, U01 DK53734, U01 DK53732, U01 DK53746, and U01 DK53738.

No information available

Boehringer Ingelheim (USA) - provided tamsulosin and matching placebo

No information available

Bayer Corporation (USA) - provided ciprofloxacin and matching placebo.

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 19/10/2004 Yes No